Agios Pharmaceuticals (AGIO) Other Operating Expenses (2017 - 2026)

Agios Pharmaceuticals has reported Other Operating Expenses for 9 years, with the latest figure at $1.3 million in Q1 2026.

• For the quarter ending Q1 2026, Other Operating Expenses rose 21.57% year-over-year to $1.3 million; the trailing twelve-month figure through Mar 2026 stood at $3.0 million (down 98.51% YoY), and the FY2024 full-year result was $200.0 million, changed N/A from the prior year.
• Other Operating Expenses for Q1 2026 stood at $1.3 million, down from $1.7 million in the prior quarter.
• The five-year high for Other Operating Expenses was $200.0 million in Q3 2024, with the low at -$9.9 million in Q4 2022.
• Historically, Other Operating Expenses has averaged $17.3 million across 5 years, with a median of $1.4 million in 2024.
• The largest YoY upside for Other Operating Expenses was 122.6% in 2022 against a maximum downside of 475.14% in 2022.
• Agios Pharmaceuticals' Other Operating Expenses stood at -$9.9 million in 2022, then jumped by 111.19% to $1.1 million in 2023, then surged by 17950.54% to $200.0 million in 2024, then sank by 99.15% to $1.7 million in 2025, then retreated by 22.5% to $1.3 million in 2026.
• The last three Other Operating Expenses figures came in at $1.3 million (Q1 2026), $1.7 million (Q2 2025), and $1.1 million (Q1 2025), per Business Quant data.